In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
http://monitiumworldwide.com
Discover how to create multiple income streams online with this on of a
kind wealth building platform. take your 14 free trial today.
http://www.youtube.com/watch?v=k62uRyp6hiY
http://www.prestashopmanager.com/useful-articles/prestashop-export-products Watch this video to see how easy it is to Export products with our Store Manager for PrestaShop Import/Export Wizard! As you see, the export process is successful and didn't take much time and effort! Use Store Manager to save hours each day and push your business to the next level! Experience all the advantages yourself! Try Store Manager for PrestaShop now! Get a free trial at www.prestashopmanager.com !
PR Consulting at http://www.endustryinsider.com/prconsulting - Get an inside look at Mynewsdesk, a PR consultant and brand engagement platform used by 30,000+ companies around the world. The power of great Public Relations and brand engagement is big for your marketing strategy, and by choosing Mynewsdesk it can become great! 30-Day Free Trial On Any Account. No strings attached. No credit card required. You will never be charged for your first 30 days. And unless you tell us not to, your trial account will automatically revert to the Free subscription level. http://www.endustryinsider.com/prconsulting YouTube: http://www.youtube.com/watch?v=OCaR7KAblig
http://attorneydirectoryofamerica.com/phoenix-arizona-criminal_law_attorneys-attorney-directory.aspx Are you in need of a criminal law attorney in Phoenix? The criminal law firms of Phoenix listed at Attorney Directory of America have a successful track record of representing people throught the state of Arizona with a wide range of criminal issues. They represent people who are involved with criminal law issues, whether they've been personally involved or an associated entity. When it comes to criminal law, its important for you to find an attorney in Phoenix who knows how to deal with the prosecutors and prepare your case for trial should it progress to that point. Your should find a law office that is dedicated to using all of its legal skills and prowess, along with its many years of experience to assist you with this difficult time you are going through. If you have a criminal law issue, contact one of the firms at Attorney Directory of America.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children’s Hospital of Philadelphia (CHOP) co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/chop/48124/
Back by popular demand, the Recreational Boating & Fishing Foundation’s (RBFF) Take Me Fishing™ campaign is kicking off Catch A Boat 3.0, an online fishing tournament that includes a sweepstakes to win daily prizes or the grand prize boat, motor and trailer. Beginning November 29, 2010 at noon ET, boaters and anglers are invited to take part in TakeMeFishing.org’s interactive game for a chance to reel in the grand prize Stratos fishing boat, provided by the North American Fishing Club (NAFC). NAFC is also offering players a 30-day free trial membership, which includes a free issue of North American Fisherman.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/catchaboat/47487/
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
